Ublituximab structure
|
Common Name | Ublituximab | ||
|---|---|---|---|---|
| CAS Number | 1174014-05-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of UblituximabUblituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1]. |
| Name | Ublituximab |
|---|
| Description | Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ublituximab 经过糖工程改造,具有含低岩藻糖的可结晶片段 (Fc) 区域,可增强抗体依赖性细胞毒性[1]。 |
| References |
| No Any Chemical & Physical Properties |